Cantourage Group SE Logo

Cantourage Group SE

A European platform producing and distributing medical cannabis products to pharmacies.

HIGH | XMIL

Overview

Corporate Details

ISIN(s):
DE000A3DSV01
LEI:
3912003NCTLO6YHA9V48
Country:
Germany
Address:
Feurigstraße 54, 10827 Berlin
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cantourage Group SE is a leading European medical cannabis company that produces and distributes cannabis-based medicinal preparations. Founded in 2019, the company operates a 'fast-track' platform model, sourcing cannabis flowers and raw materials from a global network of cultivation partners. It manages the import and processing of these materials into EU-compliant pharmaceutical products at its European manufacturing hubs, handling all regulatory complexities. The product portfolio includes dried flowers, extracts, dronabinol, and pharma-grade cannabidiol, which are distributed to pharmacies through wholesalers. Cantourage also facilitates patient access to medical cannabis therapies through its telemedicine platform, Telecan.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-04 12:00
Regulatory News Service
Cantourage strengthens market presence in Poland with flower variety Gelato 33
English 10.7 KB
2025-10-30 10:08
Earnings Release
Q3 2025: Cantourage delivers strong operating performance in a challenging regu…
English 9.7 KB
2025-10-15 15:49
Regulatory News Service
Cabinet decision on the Medical Cannabis Act meets broad criticism / Cantourage…
English 13.0 KB
2025-10-08 13:01
Regulatory News Service
Cantourage is responding to potential developments resulting from new legal reg…
English 8.3 KB
2025-10-01 09:47
Board/Management Information
Cantourage Strengthens Capital Markets Presence: New Head of Investor Relations…
English 7.4 KB
2025-10-01 09:39
Director's Dealing
Cantourage Group SE: Philip Schetter, Acquisition of 188,639 Shares as Part of …
English 6.1 KB
2025-09-04 09:00
Business and Financial Review
Cantourage Group SE Update
German 12.5 KB
2025-07-09 18:42
Board/Management Information
Ad-hoc-Mitteilung nach Art. 17 Marktmissbrauchsverordnung - Cantourage Group SE…
German 4.6 KB
2025-05-20 07:51
Earnings Release
Cantourage achieves strong and profitable growth in the first quarter of 2025
English 7.4 KB
2025-05-15 07:07
Earnings Release
Cantourage achieves another record revenue: EUR 11.1 million in April 2025
English 6.6 KB
2025-04-11 09:03
Earnings Release
Ad-hoc: Record quarter for Cantourage-Group: EUR 25.6 million revenue in Q1 202…
English 6.8 KB
2025-04-10 08:52
Earnings Release
Record quarter for Cantourage-Group: EUR 25.6 million revenue in Q1 for the fi…
English 9.0 KB
2025-03-11 08:31
Earnings Release
Cantourage Group SE: Starker Jahresendspurt und anhaltendes Wachstum in 2025
German 7.6 KB
2025-03-10 08:31
Earnings Release
Cantourage Group SE: Starker Jahresendspurt und anhaltendes Wachstum in 2025
German 7.6 KB
2025-01-16 07:30
Earnings Release
Legalization of cannabis brings strong growth: Cantourage Group SE increases it…
English 10.0 KB

Automate Your Workflow. Get a real-time feed of all Cantourage Group SE filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cantourage Group SE

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cantourage Group SE via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-01-02 Think.Health Projekt M GmbH & Co. KG Close relation Sell None 72,010.80 EUR
2024-11-25 PiFriva Verwaltungs- und Beteiligungs-GmbH Close relation Sell None 200,000.00 EUR
2024-09-13 PiFriva Verwaltungs- und Beteiligungs-GmbH Close relation Sell None 105,000.00 EUR
2024-07-18 PiFriva Verwaltungs- und Beteiligungs-GmbH Close relation Sell None 140,000.00 EUR
2024-06-06 HOFY4 GmbH Close relation Sell None 345,000.00 EUR
2024-05-27 HOFY4 GmbH Close relation Sell None 7,400.00 EUR
2024-05-17 HOFY4 GmbH Close relation Sell None 140,000.00 EUR
2024-05-17 HOFY4 GmbH Close relation Sell None 1,080.00 EUR
2024-02-21 HOFY4 GmbH Close relation Sell None 63,205.88 EUR
2024-02-14 Think.Health Projekt M GmbH & Co. KG Close relation Sell None 82,415.57 EUR

Peer Companies

ArcticZymes Technologies Logo
Develops novel enzymes from Arctic organisms for diagnostics, therapeutics, and biopharma.
Norway
AZT
Arcturus Therapeutics Holdings Inc. Logo
Develops mRNA therapeutics and vaccines for rare respiratory, liver, and infectious diseases.
United States of America
ARCT
Arcus Biosciences, Inc. Logo
A clinical-stage biopharma developing small molecule and antibody combination therapies for cancer.
United States of America
RCUS
Arcutis Biotherapeutics, Inc. Logo
Develops and commercializes non-steroidal therapies for immune-mediated skin diseases.
United States of America
ARQT
ARDELYX, INC. Logo
Biopharma developing first-in-class drugs for cardiorenal and GI diseases like IBS-C and CKD.
United States of America
ARDX
ARECOR THERAPEUTICS PLC Logo
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
United Kingdom
AREC
argenx SE Logo
Develops first-in-class antibody therapies for severe autoimmune diseases.
Netherlands
1AE
Armata Pharmaceuticals, Inc. Logo
Developing bacteriophage therapeutics for antibiotic-resistant infections.
United States of America
ARMP
AroCell AB Logo
Develops and markets diagnostic tests for monitoring cancer and bacterial diseases.
Sweden
AROC
ArriVent BioPharma, Inc. Logo
A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.
United States of America
AVBP

Talk to a Data Expert

Have a question? We'll get back to you promptly.